Median (IQR) Rosiglitazone (n=29) P (within group) Placebo (n=32) P (within group) P (between groups)
Limb fat, grams +448 (138, 1670) <0.001 +153 (-100, 682) <0.03 0.02
BMI, kg/m2 + 0.9 (0.08, 1.6) <0.001 + 0.5 (-0.08, 1.3) 0.03 0.24
F2 isoprostanes, ng/mL +0.019 (-0.002, 0.036) 0.003 +0.017 (-0.003, 0.032) 0.001 0.078
sTNFR-I, pg/mL +733.8 (318.5, 9891.3) <0.001 +973.3 (373.3, 8662.9) <0.001 0.98
sTNFR-II, pg/mL +1722.4 (872.9, 5951.9) <0.001 +1586.9 (994.7, 5552.8) <0.001 0.97
IL-6 , pg/mL +0.2 (-9.0, 34.2) 0.30 +1.4 (-5.2, 16.9) 0.29 0.92
hs CRP, mg/L -4.6 (-11.1, -0.9) <0.001 -1.5 (-8.8, 0.18) 0.02 0.11
mtDNA, copies/cell (n=57) +41 (-14, 66) (n=27) 0.08 +29 (-36, 67) (n=30) 0.38 0.54
PPAR-γ/  GAPDH ratio (n=57) -6.8% (-7.2%, -0.4%) (n=27) 0.32 -0.5% (-7.4%, 4.3%) (n=30) 0.86 0.54
Table 2: Changes over 48 weeks.
Goto home»